TOP > 外国特許検索 > iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF

iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF 新技術説明会

外国特許コード F150008135
掲載日 2015年2月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP084374
国際公開番号 WO 2014098243
国際出願日 平成25年12月20日(2013.12.20)
国際公開日 平成26年6月26日(2014.6.26)
優先権データ
  • 特願2012-280259 (2012.12.21) JP
発明の名称 (英語) iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF 新技術説明会
発明の概要(英語) Provided are: a monoclonal antibody capable of recognizing a lipid substance that is present on the surface of iPS and ES cells as an epitope and not recognizing EC cells; the aforesaid antibody having a cytotoxicity to target cells; a method for preparing a uniform mass of differentiated cells containing no undifferentiated cells, said method comprising contacting a mass of cells having been differentiated from iPS or ES cells with the aforesaid antibody and collecting surviving cells; an agent for cell transplantation therapy, said agent comprising a mass of differentiated cells obtained by the aforesaid method, etc.
従来技術、競合技術の概要(英語) BACKGROUND ART
Human induced pluripotent stem cell (iPS cell) by an established, with the use of a pluripotent stem cell transplantation treatment for the practical application of the door is opened. For example, such as Parkinson's disease or diabetes type I in the case of chronic disease, to establish iPS cells from the patient in the, cells necessary for the induction of differentiated can be autologous to the patient if the, human embryonic stem cells (ES cells) associated with the use of ethical issues (that is, life of the destruction of early embryos can also be said that bud break) or at the time of implantation can be to avoid the problem of rejection. On the other hand, in the establishment of iPS cells to from a 2-3 months at the shortest until induction are necessary, such as spinal cord injury or fulminant hepatitis is a disease that requires an early treatment, various HLA type of iPS cells or differentiated cells derived therefrom and banking, they can be used to be considered in the allograft.
However, such as ES cells or iPS cells such as pluripotent stem cells to differentiate into cardiac nerve cells and are cultured under conditions, differentiated cells remain undifferentiated cells in the population, the cause of tumorigenesis (teratoma, carcinogenesis) and, further iPS cells, initialized to the artificial cells but also causes the problem of safety of a specific (i.e., c-Myc such as proto-oncogene with the introduction of the use of viral vectors by the tumorigenesis of risk, that is from a somatic cell depending on the type of risk such as tumorigenesis by differentiation resistance) also suffers. In this way, a reproducing a pluripotent stem cell to a practical use of the transplantation treatment, which overcomes the problems of tumorigenesis is essential. Cell-derived iPS so far is suppressing of carcinogenesis, cancer gene combinations have reprogramming factor does not include, the use of non-viral vectors, such as a protein by the introduction in the establishment of iPS cells established from the viewpoint of a safer iPS has been made various attempts have been made. However, these are some of the risk of the production of iPS in the suppression of carcinogenesis by devising the indirect approach and is not intended to, can be prevented from being completely is not at a level of carcinogenesis. In addition, a common pluripotent stem cells ES cells but also causes the remaining tumorigenesis by undifferentiated cells (target cells other than many types of cells are mixed to form a teratoma mass) also to a risk, an effective resolution is not provided.
However, sugar chain recognizing antibody is, a change in cell surface sugar chain of the probe and the microtopography of the helmet, human iPS/ES cells are also commonly used as a marker antibody. That is, SSEA3, and SSEA4 of the epitopes comprise glycolipids, TRA-1-60, one of the epitopes comprise TRA-1-81 is keratan sulfate. However, most of these existing antibody, cell EC epitamial (embryonal carcinoma cell, fetal cancer cells) was obtained as an immunogen and, in addition to EC iPS/ES cells also react with the cells (cancer cells) (non-patent document 1). Therefore, stem cell research and regenerative medicine in research, does not react EC cells, an antibody that reacts only with the appearance of iPS/ES cells has been expected. Recently, Choo is, human ES cells is used as an immunogen, and does not react with anti-human ES cell EC cell antibodies (mAb84) is reported (patent document 1), this antibody also reacts to the human iPS cells is not described whether or not (patent document 2).
The inventors of the present invention, human iPS cells (Tic) immunizing a mouse as an immunogen, obtained for hybridomas, human iPS cells and human EC cells by performing differential screening, cell EC iPS/ES cells positive and the negative antibody (R-10 g) were successfully obtained (Patent Document 2). This antibody is, iPS/ES binding proteins on the cell surface, or TRA-1-60 TRA-1-81 is different from the epitope recognize keratan sulfate. However, the cell is a human iPS/ES R-10 g does not have a cytotoxic activity, the antibody, the differentiated cell population remaining in human iPS/ES is used to remove cells, flow cytometry or affinity support separation using operations become necessary.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • THE RITSUMEIKAN TRUST
  • NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION
  • 発明者(英語)
  • KAWASAKI, Toshisuke
  • KAWASAKI, Nobuko
  • FURUE, Miho
  • KAWABATA, Kenji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close